BD of the United States enters the low-end market of generic drugs

Source: first financial daily May 13, 2013, the world's largest medical technology company, BD, which entered the Chinese market 20 years ago and barely spoke, suddenly announced a series of ambitious major adjustments "Entering the field of generic drugs" in the global scope, we have entered the market of generic drugs from the field of medical technology In the Chinese market, we are entering the low-end market that has never been involved through cooperation with dealers Now, it seems that the performance is relatively satisfactory " Recently, Deng Jianmin, BD's global vice president and general manager of China, said in an interview with first financial daily "In 2012, sales in the Chinese market increased by 24.8%; this year, our sales will definitely be higher than that Compared with the scale of business three years ago, BD China's goal this year has basically doubled, and we are very optimistic about the Chinese market " Deng Jianmin disclosed to this newspaper BD's financial report for the first quarter of fiscal year 2013 shows that BD's global revenue during the reporting period was US $1.9 billion, an increase of 3.7% over the same period of the previous fiscal year Vincent forlenza, Global CEO and President of BD, said in a letter to shareholders at the beginning of the year: "the growth momentum of emerging markets is gratifying, with sales accounting for 23% of the whole company, and the driving force behind it makes us increase investment for the second consecutive year." At this stage, BD has more than 10000 products, of which six business divisions in China have hundreds of products In addition to a variety of products, BD may put further performance growth on cross domain investment "Our first pre filled drug, diphenhydramine, has just been approved by the FDA In succession, we will launch many of these new products, and the listing in China is also in progress." Deng Jianmin revealed Different from the previous pure needle tube equipment for injection, insulin, antiallergic drugs, acute heart failure and other commonly used or urgently needed drugs are pre filled into the injection equipment for sealing, so as to extend into the pharmaceutical field Such a change has a large number of clinical needs, and is also a predictable development direction of clinical medicine and pharmacy "This is an inevitable stage in the development of clinical medicine The more developed countries demand more, so we decided to adjust our market," Deng Jianmin told reporters "In the United States, there are about 50 kinds of drugs that have been out of stock, all of which have passed the patent period There are about 57 kinds, and the market size is more than one billion dollars in the United States alone." "This is the path to enter the generic drug market with technical uniqueness This technical barrier is relatively high, and there is no second one that can do it now It requires the basis of medical devices and the transmission of active ingredients of drugs These two points have been the focus of our research in the past 115 years." Deng Jianmin said According to McKinsey's forecast, China's medical device market will maintain an annual growth rate of 16% in the next few years This year, the market will be close to $40 billion In addition to the tertiary hospital market, BD's penetration into the vast low-end market in China is also being closely promoted, and the cooperation with state-owned pharmaceutical equipment under the state-owned pharmaceutical group, a central enterprise, is beginning to emerge "Our cooperation has been carried out for a period of time, but it has not been fully spread across the country At present, the progress is very smooth They help us to do distribution and post service in some low-end markets We hope to have a long-term strategic cooperation and become a national network in the future." Deng Jianmin revealed This is the first time BD officially confirmed its cooperation and progress with Sinopharm At present, BD has tried out the distribution mode of low-end market in Guizhou, Shaanxi, Henan and Shanxi provinces, and optimized the sales plan with the business mode suitable for the local characteristics.